DMT use: Perceptions and Practice in Canada – Share your experience
Click here to complete the survey on DMT use: Perceptions and Practice in Canada
MSology would like to invite you to participate in a national initiative, DMT use: Perceptions and Practice in Canada. The objective is to survey MS physicians, nurses and persons with multiple sclerosis (MS) about disease-modifying therapies* (DMTs).
Many factors can influence people with MS either to start treatment or not. People have very differing views on the benefits of treatment, the side effects and long-term safety of medications, their convenience and impact on lifestyle, the financial burden and more.
If you are a person who has received a diagnosis of MS, we want to hear from you! Your perceptions and opinions are critical to telling the story of DMT use in Canada. The multiple-choice questionnaire will take approximately 15 minutes to complete, and your responses will remain anonymous and confidential. Help us to understand your experience and views so we can develop the educational tools and support services that will address your needs. Highlights from the survey will be featured in an upcoming series on MSology.
Click here to complete the survey on DMT use: Perceptions and Practice in Canada
*Disease-modifying therapies in Canada include: interferons (Avonex, Rebif, Betaseron), glatiramer acetate (Copaxone), fingolimod (Gilenya), dimethyl fumarate (Tecfidera), anti-CD20s (Kesimpta, Ocrevus), cladribine (Mavenclad), natalizumab (Tysabri), and alemtuzumab (Lemtrada).
Share this article
Facebook Twitter pin it! Email
Related Posts
March 25, 2025Assessing disability – the great disconnect
March 18, 2025Metabolic age – new data on MS diets
March 11, 2025Virus activity may make MS more active
February 14, 2025People with MS are often undervaccinated
November 29, 2024Lifestyle and MS: New research from ECTRIMS
Back
